Use of biomarkers in inflammatory bowel disease

Iskandar, 2012, Biomarkers in inflammatory bowel disease: current practices and recent advances, Transl Res, 159, 313, 10.1016/j.trsl.2012.01.001 Miranda García, 2015, Concordancia entre la actividad clínica y los marcadores biológicos en la enfermedad inflamatoria intestinal, Med Clin (Barc), 144, 9, 10.1016/j.medcli.2013.09.047 Sands, 2015, Biomarkers of inflammation in inflammatory bowel disease, Gastroenterology, 149, 1275, 10.1053/j.gastro.2015.07.003 Niederau, 1997, Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis, Hepatogastroenterology, 44, 90 Florin, 2006, Clinically active Crohn's disease in the presence of a low C-reactive protein, Scand J Gastroenterol, 41, 306, 10.1080/00365520500217118 Vermeire, 2004, C-reactive protein as a marker for inflammatory bowel disease, Inflamm Bowel Dis, 10, 661, 10.1097/00054725-200409000-00026 Barnes, 2004, Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine, J Pediatr Gastroenterol Nutr, 38, 509, 10.1097/00005176-200405000-00009 Oussalah, 2010, Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn's disease, Aliment Pharmacol Ther, 32, 1135, 10.1111/j.1365-2036.2010.04459.x Ge, 2016, Procalcitonin in Crohn's disease with fever episodes, a variable to differentiate intra-abdominal abscess from disease flares, Int J Surg, 36, 34, 10.1016/j.ijsu.2016.10.011 Almousa, 2018, Elevation of serum pyruvate kinase M2 (PKM2) in IBD and its relationship to IBD indices, Clin Biochem, 53, 19, 10.1016/j.clinbiochem.2017.12.007 Norouzinia, 2017, Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment, Gastroenterol Hepatol Bed Bench, 10, 155 Jürgens, 2010, Disease activity, ANCA, and IL23R geno-type status determine early response to infliximab in patients with ulcerative colitis, Am J Gastroenterol, 105, 1811, 10.1038/ajg.2010.95 Singh, 2013, Meta-analysis: serological markers and the risk of acute and chronic pouchitis, Aliment Pharmacol Ther, 37, 867, 10.1111/apt.12274 Amcoff, 2016, Concordance in anti-OmpC and anti-I2 indicate the influence of genetic predisposition: results of a European Study of Twins with Crohn's Disease, J Crohns Colitis, 10, 695, 10.1093/ecco-jcc/jjw021 Ungar, 2014, The temporal evolution of antidrug anti-bodies in patients with inflammatory bowel disease treated with infliximab, Gut, 63, 1258, 10.1136/gutjnl-2013-305259 Lopez, 2017, Fecal biomarkers in inflammatory bowel disease, J Gastroenterol Hepatol, 32, 557, 10.1111/jgh.13611 Summerton, 2002, Fecal calprotectin: a marker of inflammation throughout the intestinal tract, Eur J Gastroenterol Hepatol, 14, 841, 10.1097/00042737-200208000-00005 Donato, 1999, Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type, Biochim Biophys Acta, 1450, 191, 10.1016/S0167-4889(99)00058-0 Ryckman, 2003, Proinflammatory activities of S100: Proteins S100A8 S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion, J Immunol, 170, 3233, 10.4049/jimmunol.170.6.3233 Gisbert, 2009, Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease, Dig Liver Dis, 41, 56, 10.1016/j.dld.2008.05.008 Bjerke, 1993, Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes, Gut, 34, 1357, 10.1136/gut.34.10.1357 Rodrigo, 2007, Calprotectina fecal, Rev Esp Enferm Dig, 99, 683, 10.4321/S1130-01082007001200001 Poullis, 2003, Emerging role of calprotectin in gastroenterology, J Gastroenterol Hepatol, 18, 756, 10.1046/j.1440-1746.2003.03014.x Rendek, 2016, Effect of oral diclofenac intake on faecal calprotectin, Scand J Gastroenterol, 51, 28, 10.3109/00365521.2015.1066421 Von Roon, 2007, Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy, Am J Gastroenterol, 102, 803, 10.1111/j.1572-0241.2007.01126.x Tursi, 2014, Increased faecal calprotectin predicts recurrence of colonic diverticulitis, Int J Colorectal Dis, 29, 931, 10.1007/s00384-014-1884-0 Ertekin, 2010, Fecal calprotectin concentration in celiac disease, J Clin Gastroenterol, 44, 544, 10.1097/MCG.0b013e3181cadbc0 Montalto, 2008, Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth, Dig Dis, 26, 183, 10.1159/000116777 Kim, 2017, Fecal calprotectin level reflects the severity of Clostridium difficile infection, Ann Lab Med, 37, 53, 10.3343/alm.2017.37.1.53 García Sánchez, 2006, Precisión diagnóstica de la calprotectina fecal para predecir una colonoscopia patológica, Med Clin (Barc), 127, 41, 10.1157/13090002 Menees, 2015, A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS, Am J Gastroenterol, 110, 444, 10.1038/ajg.2015.6 Lozoya Angulo, 2017, Calprotectina fecal, marcador eficaz en la diferenciación de enfermedades inflamatorias intestinales y trastornos funcionales gastrointestinales, Gastroenterol Hepatol, 40, 125, 10.1016/j.gastrohep.2016.04.009 Van Rheenen, 2010, Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis, BMJ, 341, c3369, 10.1136/bmj.c3369 Yang, 2014, Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children, Clin Gastroenterol Hepatol, 12, 253, 10.1016/j.cgh.2013.06.028 Brookes, 2018, Practical guidance on the use of faecal calprotectin, Frontline Gastroenterol, 9, 87, 10.1136/flgastro-2016-100762 Siddiqui, 2017, Update on clinical and research application of fecal biomarkers for gastrointestinal diseases, World J Gastrointest Pharmacol Ther, 8, 39, 10.4292/wjgpt.v8.i1.39 Seenan, 2015, Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations?, Frontline Gastroenterol, 6, 156, 10.1136/flgastro-2014-100467 Pennazio, 2015, Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline, Endoscopy, 47, 352, 10.1055/s-0034-1391855 Egea Valenzuela, 2015, Calprotectina fecal como predictor de lesiones inflamatorias en intestino delgado diagnosticadas con cápsula endoscópica, Rev Esp Enferm Dig, 107, 211 Bar-Gil Shitrit, 2017, A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy, Scand J Gastroenterol, 52, 328, 10.1080/00365521.2016.1253769 Kopylov, 2016, Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis, Eur J Gastroenterol Hepatol, 28, 1137, 10.1097/MEG.0000000000000692 Egea Valenzuela, 2018, Development and validation of a scoring index to predict the presence of lesions in capsule endoscopy in patients with suspected Crohn's disease of the small bowel: a Spanish multicenter study, Eur J Gastroenterol Hepatol, 30, 499, 10.1097/MEG.0000000000001083 Egea Valenzuela, 2016, Calprotectina y proteína C reactiva se asocian a hallazgos en cápsula endoscópica de pacientes con sospecha de enfermedad de Crohn de intestino delgado, Rev Esp Enferm Dig, 108, 394 Höög, 2014, Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease, Scand J Gastroenterol, 49, 1084, 10.3109/00365521.2014.920915 Lee, 2017, Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo Endoscopic Subscore in patients with ulcerative colitis, BMC Gastroenterol, 17, 110, 10.1186/s12876-017-0669-7 Theede, 2014, The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment, Scand J Gastroenterol, 49, 418, 10.3109/00365521.2014.883427 De Vos, 2012, Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis, J Crohns Colitis, 6, 557, 10.1016/j.crohns.2011.11.002 Puolanne, 2017, Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic inflammatory bowel disease, Dig Dis Sci, 62, 3123, 10.1007/s10620-017-4770-0 Zittan, 2016, Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn's disease, Inflamm Bowel Dis, 22, 623, 10.1097/MIB.0000000000000652 Aggarwal, 2017, Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse, Gastrointest Endosc, 86, 1070, 10.1016/j.gie.2017.09.011 Baveye, 1999, Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process, Clin Chem Lab Med, 37, 281, 10.1515/CCLM.1999.049 Mooiweer, 2014, Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation, Inflamm Bowel Dis, 20, 307, 10.1097/01.MIB.0000438428.30800.a6 Shi, 2017, Accuracy of faecal immunochemical test to predict endoscopic and histological healing in ulcerative colitis: a prospective study based on validated histological scores, J Crohns Colitis, 11, 1071, 10.1093/ecco-jcc/jjx088 Di Ruscio, 2017, Surrogate fecal biomarkers in inflammatory bowel disease: rivals or complementary tools of fecal calprotectin?, Inflamm Bowel Dis, 24, 79 Kochhar, 2017, Utility of biomarkers in the management of inflammatory bowel disease, Curr Treat Options Gastroenterol, 15, 105, 10.1007/s11938-017-0129-z Schönauen, 2018, Circulating and fecal microRNAs as biomarkers for inflammatory bowel diseases, Inflamm Bowel Dis, 24, 1447, 10.1093/ibd/izy046 Yau, 2013, Proteomics and metabolomics in inflammatory bowel disease, J Gastroenterol Hepatol, 28, 1076, 10.1111/jgh.12193 Barnes, 2016, New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes, Inflamm Bowel Dis, 22, 2956, 10.1097/MIB.0000000000000903 Marlicz, 2018, Emerging concepts in non-invasive monitoring of Crohn's disease, Therap Adv Gastroenterol, 11, 10.1177/1756284818769076 Patel, 2014, Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study, Aliment Pharmacol Ther, 40, 498, 10.1038/mt.2013.239